APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

497

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Advanced Cancer
Renal Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
NSCLC
Lung Cancer
Brain Tumor
Glioblastoma Multiforme
EGFR Gene Mutation
MET Amplification
HGF
Thyroid Cancer
Pancreatic Cancer
Colon Cancer
MET Alteration
MET Fusion
Exon 14 Skipping

Interventions

DRUG: APL-101 Oral Capsules

Sponsor

Apollomics Inc.